Business
CURE Pharmaceutical CBD Oral Thin Film Pharmacokinetic Study Shows Improved Bioavailability Compared to CBD Soft Gel
CURE Pharmaceutical CBD Oral Thin Film Pharmacokinetic Study Shows Improved Bioavailability Compared to CBD Soft Gel.
About this update from Avenir Wellness Solutions Inc.
[{"type":"text","content":"\n OXNARD, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced that its 25mg cannabidiol (CBD) oral thin film (OTF) showed improved bioavailability of cannabidiol in healthy subjects, compared with 25mg soft gels. Specifically, a pharmacokinetic (PK) study in 14 healthy adults showed a significantly higher serum concentration (Cmax) and significantly faster absorption (Tmax) from CURE's CBD OTF dose form than from a commercially available CBD soft gel. The study also suggests that the CUREform™ delivery platform, which entails solubilization and encapsulation of the molecule, might deliver better results than solubilization alone, as used in the soft gel product, and may play a synergistic or additive role in bioavailability. CBD, a phytocannabinoid compound, has limited oral bioavailability because it is fat soluble, which is difficult for the body to absorb.  It also degrades extensively via the first pass metabolism.  CUREform™, CURE’s proprietary delivery platform, is uniquely designed to overcome such obstacles and deliver active ingredients more effectively. “This study indicates that CUREform technology improved cannabinoid bioavailability, potentially allowing for a lower dose, which may facilitate a reduction in side effects and better compliance,” said Vered Gigi, PhD, Chief Scientific Officer of CURE Pharmaceutical. “We believe that our technology could be effectively applied to other molecules that have bioavailability challenges achieving multiple patient benefits.” CURE’s CEO Rob Davidson, stated, “CURE’s delivery platform, which includes the encapsulation technology gained via the Chemistry Holdings acquisition, might have commercial applications for CBD, especially when given in high doses.  Moreover, when we consider that CURE’s buccal, or transmucosal, application technology may avoid first pass drug metabolism, we might see further improvements beyond those observed in this study. The potential to meet a large consumer base and unmet medical need is compelling.” About the StudyThis open-label, randomized, single-dose, crossover study of 14 healthy adults compared the pharmacokinetics of a commercially available soft gel formulation (l...